PT1233787E - Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro - Google Patents

Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro

Info

Publication number
PT1233787E
PT1233787E PT00976116T PT00976116T PT1233787E PT 1233787 E PT1233787 E PT 1233787E PT 00976116 T PT00976116 T PT 00976116T PT 00976116 T PT00976116 T PT 00976116T PT 1233787 E PT1233787 E PT 1233787E
Authority
PT
Portugal
Prior art keywords
therapeutic use
inhibitor
gheterotrimeral
anticancerosous
transducing
Prior art date
Application number
PT00976116T
Other languages
English (en)
Inventor
Thomas D Gordon
Barry A Morgan
Prevost Gregoire
Lonchampt Marie-Odile
Original Assignee
Conseils Rech S Et D Applic Sc
Scras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9914037A external-priority patent/FR2800616B1/fr
Priority claimed from FR0000104A external-priority patent/FR2803524B1/fr
Application filed by Conseils Rech S Et D Applic Sc, Scras filed Critical Conseils Rech S Et D Applic Sc
Publication of PT1233787E publication Critical patent/PT1233787E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT00976116T 1999-11-09 2000-11-08 Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro PT1233787E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9914037A FR2800616B1 (fr) 1999-11-09 1999-11-09 Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR0000104A FR2803524B1 (fr) 2000-01-06 2000-01-06 Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer

Publications (1)

Publication Number Publication Date
PT1233787E true PT1233787E (pt) 2005-04-29

Family

ID=26212071

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00976116T PT1233787E (pt) 1999-11-09 2000-11-08 Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro

Country Status (15)

Country Link
US (3) US7034024B1 (pt)
EP (2) EP1430934A1 (pt)
JP (1) JP2003513940A (pt)
AT (1) ATE284224T1 (pt)
AU (1) AU1400401A (pt)
CA (1) CA2390317C (pt)
CZ (1) CZ20021550A3 (pt)
DE (1) DE60016625T2 (pt)
DK (1) DK1233787T3 (pt)
ES (1) ES2234692T3 (pt)
HU (1) HUP0203241A3 (pt)
PL (1) PL204716B1 (pt)
PT (1) PT1233787E (pt)
RU (1) RU2298417C2 (pt)
WO (1) WO2001034203A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR2834289B1 (fr) 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
KR100594353B1 (ko) * 2002-05-28 2006-07-03 주식회사 엠디바이오알파 신규한 인삼잎 및 줄기 다당체, 그 제조방법 및 그를활성성분으로 함유하는 항암제 및 항암보조제 조성물
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2877667B1 (fr) 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
CA2620223A1 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
AR077463A1 (es) 2009-07-09 2011-08-31 Irm Llc Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
DE102009033392A1 (de) * 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
MX368615B (es) * 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
MA39792B1 (fr) 2014-03-26 2019-12-31 Hoffmann La Roche Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
CN106317057B (zh) * 2015-07-02 2019-02-01 北京桦冠医药科技有限公司 具有咪唑并吡嗪类衍生物，其制备及其在医药上的应用
UA123362C2 (uk) 2015-09-04 2021-03-24 Ф. Хоффманн-Ля Рош Аг Феноксиметильні похідні
AU2018233079B9 (en) 2017-03-16 2021-07-22 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as dual ATX/CA inhibitors
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
AU2018260414A1 (en) 2017-04-24 2019-10-17 Novartis Ag Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone and combinations thereof
CN112480122B (zh) * 2020-11-24 2022-03-22 中山大学 一种四氢咪唑[1,2-a]吡嗪类化合物、组合物及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH0517353A (ja) * 1991-07-10 1993-01-26 Kanebo Ltd 制癌作用増強剤
US5731334A (en) * 1994-01-11 1998-03-24 The Scripps Research Institute Method for treating cancer using taxoid onium salt prodrugs
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
EP0865440B1 (en) * 1995-12-08 2002-04-03 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
WO1999007705A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
HUP0102473A3 (en) * 1997-12-22 2003-07-28 Schering Corp Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase

Also Published As

Publication number Publication date
CA2390317A1 (fr) 2001-05-17
EP1233787A1 (fr) 2002-08-28
ES2234692T3 (es) 2005-07-01
JP2003513940A (ja) 2003-04-15
DE60016625D1 (de) 2005-01-13
EP1430934A1 (fr) 2004-06-23
AU1400401A (en) 2001-06-06
EP1233787B8 (fr) 2005-05-18
HUP0203241A2 (hu) 2003-02-28
RU2298417C2 (ru) 2007-05-10
RU2002115262A (ru) 2004-01-27
DK1233787T3 (da) 2005-08-15
US7034024B1 (en) 2006-04-25
PL204716B1 (pl) 2010-02-26
ATE284224T1 (de) 2004-12-15
CA2390317C (fr) 2010-03-23
DE60016625T2 (de) 2005-12-22
PL356028A1 (en) 2004-06-14
EP1233787B1 (fr) 2004-12-08
US20060074078A1 (en) 2006-04-06
HUP0203241A3 (en) 2006-07-28
US20090270341A1 (en) 2009-10-29
WO2001034203A1 (fr) 2001-05-17
CZ20021550A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
PT1233787E (pt) Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro
SE9800836D0 (sv) New Compounds
HUP0301281A2 (hu) Új gyógyászati készítmény
PT876387E (pt) Utilizacao de roxitromicina para a preparacao de um medicamento para melhorar a actividade biologica e antiviral de inibidores da protease
ATE318590T1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
EE200000770A (et) Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
Spartalis et al. Histone deacetylase inhibitors and anaplastic thyroid carcinoma
DE60001271D1 (de) Hydroxymatairesinol in der krebs-prevention
HUP0402506A2 (hu) FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére
HUP0400668A2 (hu) A hiszton-dezacetiláz inhibitor gyógyászati alkalmazása, és eljárás tumorellenes hatásának kiértékelésére
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
ME00578A (en) Use of gastrointestinal lipase inhibitors
DE69725860D1 (de) PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
EA200501019A1 (ru) Противораковое лекарственное средство, фармацевтическая композиция и способ ингибирования размера опухоли (варианты) на его основе
DK0825857T3 (da) Anvendelse af gabapentin og derivater deraf til behandling af mani og bipolær lidelse
ATE226094T1 (de) Verfahren zur arzneistoffabgabe mittels gentherapie
YU16399A (sh) ) UPOTREBA INHIBITOR H +, K+ - ATP- aze I FARMACEUTSKA FORMULACIJA ZA SIMULTANU, SEPARATNU ILI SEKVENCIJALNU UPOTREBU, KOJA SADRZI INHIBITOR H +, K+-ATP- aze I GLUKOKORTIKOID INHIBITOR H +, K+- ATP- aze
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
WO2000024766A3 (en) New transcription factor of mhc class ii genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
DE60126591D1 (de) In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB
BRPI0011135B8 (pt) sistema de ministração terapêutica transdérmica contendo agente neuroléptico
WO2003077841A3 (en) Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases